Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data LISATA THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
Revenue
35.3
0
0
1
0.17
Cost of revenue
31.1
Gross profit
4.15
Research and development
16.7
15.8
7.59
10.8
9.25
17.7
13.1
12.7
11.3
7.95
Selling, general and administrative
12.8
11.8
9.39
9.3
9.89
11.5
14.1
13
General and administrative
13
12.1
10.4
Operating expenses
29.5
27.6
17
20.1
19.1
29.1
57.6
25.7
23.4
18.4
Operating income
-29.5
-27.6
-17
-20.1
-19.1
-29.1
-57.6
-25.7
-22.4
-18.2
Interest expense
1.78
0.38
0.01
0
Other non-operating income
-1.76
-0.11
0.82
0.74
0.13
0.08
0.9
2.54
1.63
0.66
Pre-tax income
-31.3
-27.7
-16.2
-19.4
-19
-29
-56.7
-23.2
-20.8
-17.5
Income tax
0
-11.5
0
0
-10.9
-1.51
-2.48
-2.33
-0.8
-0.96
Income from continuing operations
-31
-16
-16.2
Net income
-32.7
23
-16.2
-19.4
-8.15
-27.5
-54.2
-20.8
-20
-16.6
EBITDA
-29
-27.2
-16.8
-20
-19
-29
-57.5
-25.5
-22.2
-18.1
EPS, basic
-74.35
38.14
-24.88
-28.01
-7.90
-7.45
-10.47
-2.58
-2.40
-1.91
EPS, diluted
-74.35
38.14
-24.88
-28.01
-7.90
-7.45
-10.47
-2.58
-2.40
-1.91
Shares, basic (weighted)
0.44
0.6
0.65
0.69
1.04
3.69
5.18
8.07
8.33
8.69
Shares, diluted (weighted)
0.44
0.6
0.65
0.69
1.04
3.69
5.18
8.07
8.33
8.69
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
Cash and equivalents
7.08
29.2
10.3
14
16.5
24.6
32.2
22.6
16.2
16
Receivables
0.14
0.23
0
0.9
0
Other current assets
1.9
1.31
1.05
0.82
0.76
1.21
2.65
3.39
2.43
1.75
Total current assets
24.6
61.4
44.1
26
35.3
96.2
71.9
53.9
34.6
17.7
Property, plant and equipment
0.71
0.26
0.17
0.1
0.06
0.06
0.3
0.18
0.07
0.02
Lease right-of-use assets
0.91
0.57
0.72
0.49
0.31
0.14
0
Goodwill
7.01
Intangible assets
2.31
0
0.4
0.4
0.4
0.4
Other non-current assets
1.58
1.72
0.31
1.08
0.61
0.76
0.53
0.33
0.16
0.02
Total assets
53.5
63.4
44.6
27.2
36
97
73
54.7
35
17.7
Accounts payable
2.23
1.34
0.76
1.49
1.02
1.93
2.66
2.42
1.28
1.02
Accrued liabilities
2.66
7.81
4.86
4.49
2.49
2.59
3.73
4.17
4.33
2.05
Deferred revenue
5.1
2.45
2.58
Short-term debt
3.13
0
Total current liabilities
21.2
9.31
5.62
5.98
3.51
4.52
6.38
6.59
5.61
3.07
Long-term debt
2.52
0
Lease liabilities
0.25
0.49
0.31
0.14
0
0
Other non-current liabilities
0.39
3.87
1.51
0.62
0.25
0.49
0.33
0.21
0.07
0.07
Total liabilities
30
13.2
7.13
6.6
3.76
5.01
6.71
6.8
5.69
3.14
Total debt
5.65
0
Paid-in capital
410
433
436
439
459
546
575
577
578
580
Retained earnings
-405
-382
-398
-417
-426
-453
-507
-528
-548
-565
Treasury stock
-0.71
-0.71
-0.71
-0.71
-0.71
-0.71
-0.71
-0.71
-0.71
-0.71
Other comprehensive income
0
-0.03
-0.03
0
-0.01
-0.07
-0.03
-0.04
-0.08
-0.04
Shareholders' equity
4.88
50.5
37.7
20.8
32.5
92.3
66.6
48.1
29.6
14.9
Minority interests
-0.82
-0.32
-0.27
-0.26
-0.25
-0.25
-0.25
-0.25
-0.25
-0.25
Total equity
4.07
50.2
37.5
20.6
32.2
92
66.3
47.9
29.3
14.6
Total liabilities and equity
53.5
63.4
44.6
27.2
36
97
73
54.7
35
17.7
Shares outstanding
0.55
0.64
0.66
0.71
1.3
3.99
7.87
8.15
8.41
8.83
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
Net income
-33.3
22.2
-16.2
-19.4
-8.14
-27.5
-54.2
-20.8
-20
-16.6
Depreciation and amortization
0.5
0.4
0.2
0.1
0.1
0.06
0.07
0.19
0.17
0.15
Stock-based compensation
2.6
2.85
2.45
1.3
1.27
2.01
2.64
2.04
1.65
1.23
Deferred income tax
0
-0.58
0
0
-10.9
-1.51
-2.48
-2.33
-0.8
-0.96
Change in receivables
-0.1
-0.1
0
-0.9
0.4
Change in inventory
-0.67
Cash from operations
-23.7
-20.9
-20
-18.9
-8.82
-22.2
-21.2
-20
-19.4
-15.9
Capital expenditures
-1.1
-0.14
-0.13
0
-0.02
-0.06
-0.29
0
0
-0.03
Purchases of investments
0
-60.2
-69.7
-32.9
-34.8
-180
-89.7
-98.5
-55.7
-9.18
Sales and maturities of investments
0
33.9
62.6
54.4
27.5
125
122
109
69.1
24.3
Cash from investing
-2.85
41.3
-4.71
21.4
-7.28
-54.9
28.9
10.1
13.2
15.1
Debt repaid
-9.35
-5.65
0
Stock issued
0
0.01
0.36
0
18.7
85.5
0.04
0.32
0.07
0.84
Cash from financing
20.9
-0.93
0.82
1.18
18.6
85.3
-0.22
0.39
-0.21
0.6
Exchange rate effect
0
-0.01
-0.02
-0.06
0.01
Net change in cash
-5.61
19.5
-23.9
3.73
2.48
8.14
7.51
-9.56
-6.38
-0.25
Free cash flow
-24.8
-21
-20.1
-18.9
-8.84
-22.3
-21.5
-20
-19.4
-16
Interest paid
1.82
0.71
0.01
0
0
0
Income taxes paid
0
0
0
0
0
0
0.01
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.17 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-16,428.0%
Operating income / revenue.
EBITDA margin
-16,364.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-15,008.0%
Pre-tax income / revenue.
Net margin
-14,621.0%
Net income / revenue.
FCF margin
-12,323.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-12,323.0%
Cash from operations / revenue.
Return on equity (ROE)
-177.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-132.6%
Net income / average total assets.
R&D / revenue
4,881.0%
Research and development expense / revenue.
Stock-based pay / revenue
1,035.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
D&A / revenue
64.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-83.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-49.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-39.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-14.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-49.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-37.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-13.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
18.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
53.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.69x
Current assets / current liabilities.
Quick ratio
3.50x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.50x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$1.35
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.35
Cash from operations / diluted weighted shares.
Book value per share
$0.90
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
105x
Market cap / revenue.
P/B
1.28x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.34x
Market cap / tangible book value, when positive.
EV/Sales
1.00x
Enterprise value / revenue.
FCF yield
-116.9%
Free cash flow / market cap.
Earnings yield
-138.7%
Net income / market cap (the inverse of P/E).
What was LISATA THERAPEUTICS, INC.'s revenue in fiscal 2024?
LISATA THERAPEUTICS, INC. reported revenue of $170.0K for fiscal 2024, 83% lower than the year before.
Was LISATA THERAPEUTICS, INC. profitable in fiscal 2024?
No. It reported a net loss of $16.6M.
How much free cash flow did LISATA THERAPEUTICS, INC. generate in fiscal 2024?
Cash from operations of $15.9M minus capital expenditures of $28.0K left free cash flow of -$16.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.